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The DNA molecule stands at the center of cancer origin and treatment. Cancer cells 
are addicted to DNA mutations and DNA replication, therapeutic non-responders are 
often based on the rate of mutations and ability to replicate DNA. Conversely, DNA, 
being the most vulnerable spot of a tumor, is also the main target for chemotherapies. 
The in-depth understanding of cellular processes upon errors in the DNA genetic code 
is therefore crucial for designing new chemotherapeutic drugs and new combinations 
of drugs; specifically, it is the main endeavor to induce and exacerbate DNA damage 
in cancer cells. The combination of new small-molecule inhibitors with established 
chemotherapeutics, to increase their effect on the tumor and to decrease the side 
effects for the patient, is currently of great interest in preclinical and clinical research. 
In this work we have investigated a small-molecule inhibitor against the DNA damage 
response kinase MK2 that increases cytotoxicity of the DNA crosslinker cisplatin but 
relieves replicative stress upon co-treatment with the nucleoside analogue 
Gemcitabine. We verified these effects using both drugs in the same biological system, 
with a dependence on the cell cycle phase. Taken together, the combination of new 
compounds with established chemotherapeutic drugs is a very promising approach to 
benefit cancer patients, but the effects can vary dependent on the specific 
chemotherapeutic and should be applied in the clinics with great care. In another 
project we have further developed the idea of cyclotherapy, i.e. using a 
pharmacological pulse activation of a tumor suppressor to halt the cell cycle, which 
protects non-transformed cells, while targeting tumor suppressor mutated cancer cells 
with DNA damaging chemotherapeutics. We used a Click Chemistry reaction of the 
nucleoside analogue 5-Vinyl-2'-deoxyuridine (5-VdU) and a novel DNA-intercalator in 
a pretargeting approach, meaning the separation of the specific targeting component 
and the cytotoxic component of a drug. Moreover, we utilized Nutlin-3a to stabilize 
p53, arresting the cell cycle in p53 proficient cells. As a result, these cells did not 
incorporate 5-VdU and were not susceptible to the novel DNA-intercalator, while p53 
-/- cells failed to be protected by Nutlin-3a. We thereby present a promising treatment 
scheme to target tumor suppressor mutated cells only, while sparing tumor suppressor 
wildtype cells. In summary, we present strategies to enhance the specificity and 
efficacy of existing chemotherapeutics, and novel compounds to selectively 
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Ever since Watson and Crick correctly described the double helical structure of 
deoxyribonucleic acid (DNA) in 19531, the molecule has been recognized as the 
carrier of genetic information, having the protagonist role in the central dogma of 
molecular biology2. To protect this genetic information, the genetic code consists of 
two complementary DNA strands and is replicated with a high fidelity in a semi-
conservative way3. The DNA remains in a supercoiled and tightly packed state for 
most of the time4, as so-called heterochromatin, protecting it from exogenous and 
endogenous stressors. However, this protected state sometimes has to be temporarily 
abandoned for vital cellular functions to occur, such as transcription, DNA replication 
and mitosis. During these processes the DNA is dissociated from histones, unwound 
and sometimes even separated and split open5. This is when the DNA is most 
vulnerable to DNA damaging stressors, which are unfortunately ubiquitous and 
multimodal6. These eventually lead to mutations on the DNA level, namely base 
substitutions, insertion and deletion mutations7. The resulting effects on the protein 
level can be either silent, moderate or, for example in case of nonsense or frameshift 
mutations, devastating. Luckily, a sophisticated and intricate molecular machinery 
detects and repairs most of these damages8, this enables life to persist in an 
environment of oxidative stress and UV irradiation. However, not all damages are 
detected and repaired, which can result in the accumulation of mutations, cellular 
aging and ultimately cancer development. One of the breakthroughs in cancer 
research was the acceptance, that cancer is a genetic disease9, making mutations 
and DNA damaging stressors the core of its origin. Consequently, DNA also emerged 
as the most effective target for early chemotherapies, as DNA damaging agents are 
able to temporarily slow tumor progression in patients10. This puts the DNA molecule 
in the center of attention for the origin and therapy of cancer. The disease is based on 
DNA mutations and is addicted to DNA replication as cells proliferate rapidly. 
Therefore, the mechanistical study of established chemotherapeutics, the discovery 
of novel anti-cancer drugs, and the synergistic combination of both are the ongoing 





1.1. The multitude of DNA damage 
 
Due to its high frequency of occurrence and ubiquity, a certain amount of DNA damage 
must be regarded as physiological for a living cell. An important classification of DNA 
damage is whether its origins are endogenous or exogenous. Sources of exogenous 
DNA damage surround us every day. As an example, all land-living species have to 
deal with DNA damaging UV irradiation during daytime, which is more intense the 
closer one gets to the equator. UV light, notably UV-A and UV-B, can cause pyrimidine 
dimer formation and induction of reactive oxygen species (ROS)11. Sources of 
endogenous DNA damage originate from within the cell. All oxygen breathing 
organisms are under constant oxidative stress, as the element of oxygen can form 
very aggressive reaction partners that disturb highly ordered biochemical structures. 
The main source of ROS originates from toxic metabolic byproducts of the oxidative 
metabolism of a cell12. Other DNA damages occur during DNA replication13 and RNA 
transcription-DNA replication collisions14. 
 
As an estimation, a human cell nucleus has to cope with more than 10.000 events of 
DNA damage per day. For example, it has to deal with frequently losing DNA bases, 
i.e. up to 5.000 depurinations15 and up to 600 depyrimidinations16. On top of that there 
are DNA backbone breakages, frequently occurring during DNA replication, in average 
50.000 single stranded breaks17 and up to 50 double stranded breaks18, which 
represent the most toxic DNA lesions to the cell. Furthermore, there are an estimated 
3.000 formations of O6-methylguanines17 and 200 cytosine deaminations17. There are 
discrepancies in age and cell types, young rats have been evaluated to carry only one 
third of the DNA damage old rats have19, and cells of the central nervous system have 
been reported to have a four-fold number of DNA abasic sites when compared to other 
organs20. These numbers are estimates and the list of DNA damage types is 
incomplete, but they should highlight the DNA damage burden that organisms have to 
deal with every day.  
 
Apart from natural occurring exogenous DNA damage, there is DNA damage 
artificially inflicted to cells for cancer therapeutic purposes. Radiotherapists utilize 
ionizing irradiation to target inoperable tumors and micro-metastases, inducing DNA 
double-stranded breaks (DSB), which become cytotoxic after a certain threshold21. 
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Also, the majority of chemotherapeutics induces DNA damage. This was historically 
unknown and only revealed after years of anti-cancer drug application to patients. One 
group of DNA damaging chemotherapeutics are alkylating agents, such as 
cyclophosphamide22, which induce cytotoxic intra- and interstrand DNA crosslinks23. 
Platinum-based anticancer drugs, such as cisplatin24, act in a similar way. 
Furthermore, the group of topoisomerase inhibitors, such as irinotecan25 against 
topoisomerase type I and etoposide26 against topoisomerase type II, induces DNA 
single-stranded breaks (SSB) and DSBs by blocking the enzymatic ligation step. 
Another group are the anthracyclins, such as doxorubicin27, which act as direct DNA 
intercalators and topoisomerase II inhibitors to primarily impact DNA replication. The 
large group of precursor analogues and nucleoside analogues, such as 
Gemcitabine28, interferes with the synthesis and incorporation of DNA and RNA 
nucleotides, they are highly effective in inducing DNA damage as they imbalance the 
nucleotide pool and therefore the synthesis of DNA itself29. Last but not least there is 
the group of peptide antibiotics, such as bleomycin30, which also induces DNA strand 
breaks. Taken together, many DNA damaging substances have been found to be 
highly effective in anti-cancer therapies, as the tumor DNA stands at the hub of 
carcinogenesis and cancer progression. The chemotherapeutic drugs Gemcitabine 
and cisplatin will be further introduced in greater detail, as they are an integral part of 
the findings in this dissertation. 
 
1.1.1 The chemotherapeutic drugs Gemcitabine and cisplatin 
 
The nucleoside analogue Gemcitabine is a deoxycytidine/pyrimidine analogue, in 
which the hydrogen residues of the 2'-carbon have been substituted by fluorine 
residues. As a prodrug, Gemcitabine is converted into its active triphosphate 
metabolite 2',2'-difluorodeoxycytidine triphosphate (dFdCTP) after cellular uptake28. In 
its active state, Gemcitabine inhibits ribonucleotide reductase to deplete nucleotide 
pools and also impedes DNA replication directly by incorporation and sterical 
hindrance of DNA polymerases31, efficiently inducing DNA damage in actively 
replicating cells29. Actively replicating cells already exhibit moderate levels of DNA 
damage stress, so-called replicative stress29, originating from endogenous and 
exogenous DNA stressors as mentioned above, but also through stalled replication 
forks, which halt at sites of damaged DNA. If the damage can be repaired, replication 
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continues, but if the damage persists, the replication fork collapses through loss of 
DNA polymerases32 and gives rise to a highly cytotoxic DSB33. Cancer cells are more 
prone to replicative stress and DNA damage in general, as they have lost 
compensation mechanisms against oxidative stress and DNA repair pathways during 
their carcinogenesis34. Therefore, Gemcitabine is able to efficiently induce DNA 
damage, especially in tumor cells actively replicating their DNA in S-phase. 
 
Similar to Gemcitabine, the platinum-agent cisplatin can also be considered a prodrug, 
as one of its chloride residues will be replaced by a water molecule in a process named 
aquation35. This reaction preferably takes place intracellularly due to the low 
concentration of chloride within the cell. The water molecule is then easily exchanged 
by N-heterocyclic bases on the DNA, a further displacement of the other chloride, with 
preferably Guanine, leads to intra- or interstrand DNA crosslinks24. These eventually 
lead to DSB formation, which are highly cytotoxic for the cell, primarily in mitosis, as a 
single unrepaired DSB can lead to structural chromosomal aberrations and cell 
death36. In summary, both Gemcitabine and cisplatin have DNA as their therapeutic 
target, but while Gemcitabine mainly hampers DNA replication in S-phase, cisplatin-
induced DSBs mainly impact mitosis. Clinically, the combination of Gemcitabine and 
cisplatin has been shown to be highly effective in comparison to other 
chemotherapeutic combinations37, this might be due to their DNA damaging effects in 
distinct cell cycle phases.  
 










Figure 1: Chemical structures of (A) Gemcitabine38 and (B) cisplatin39. 
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1.2. The DNA damage response 
 
The DNA damage response (DDR) consists of an intricate molecular machinery with 
a multitude of factors, responding to all different types of DNA damage and activating 
the correct corresponding DNA damage repair pathways40. Depending on the nature 
and the extent of DNA damage, the cellular responses might also differ in intensity, 
ranging from transcriptional regulation, cell cycle arrest and DNA repair to activation 
of apoptosis pathways. The signal transduction of the DDR mainly functions through 
phosphorylation cascades, especially in the early stages of the response. At the apex 
of the DDR stand two kinases of the phosphatidylinositol 3- kinase-related kinase 
(PIKK) family, the Ataxia-Telangiectasia-Mutated (ATM) and ATM- and Rad3-related 
(ATR) kinases41. Their downstream signal transduction upon detection of SSB and 
DSB will be introduced in greater detail. 
 
1.2.1. The ATR-Chk1 axis 
 
As previously stated, SSBs frequently form during DNA replication. The lesion is first 
detected and bound by replication protein A (RPA), which then recruits ATR and its 
interacting protein, ATRIP42. ATR is subsequently activated and phosphorylates its 
many downstream targets, of which the most prominent is Checkpoint kinase 1 
(Chk1)43. Activated Chk1 can arrest the cell cycle through different pathways. For 
instance, it inhibits cyclin dependent kinases (Cdks) by marking its negative regulators 
Cdc25A/B for proteasomal degradation44. Chk1 also activates the Wee1 kinase, which 
phosphorylates Cdk1 at the inhibitory sites Tyr15 and Thr14, halting the cell cycle at 
the G2/M checkpoint45. Inhibited Cdk1 can be activated by the Cdc25C phosphatase 
by removing the Tyr15 phosphorylation. However, Chk1 is able to phosphorylate 
Cdc25C at Ser216, marking it to be intercepted and thus inactivated by 14-3-3 
proteins46. The Chk1 kinase can therefore influence the activation of Cdks at different 







1.2.2. The ATM-Chk2 axis 
 
DSBs can originate from various sources, one of which is the prolonged stalling of the 
replication fork, which eventually leads to fork collapse. Upon DSB formation, inactive 
ATM dimers are activated through auto-phosphorylation at Ser1981 and dissociate 
into active monomers47. These are then recruited to the DSB site via the 
MRE11/RAD50/NBS1 (MRN) complex48, where they activate their primary target, the 
Checkpoint kinase 2 (Chk2), by phosphorylation at Thr6849. Similar to Chk1, Chk2 
kinase activity also leads to degradation of Cdc25 proteins and can therefore arrest 
the cell cycle upon DNA damage48. ATM and Chk2 also influence the p53 pathway, 
either by activating p53 via phosphorylation directly, or by disrupting the MDM2/p53 
interaction by MDM2 phosphorylation at Ser39549. The ATM-Chk2 axis is therefore 
able to halt the cell cycle upon incidence of DNA damage either through inactivation 
of Cdks or activation of the p53 pathway. Furthermore, ATM plays a crucial role in the 
initiation of DNA repair. The kinase phosphorylates the histone H2A isoform H2AX at 
Ser139, which is then called γh2ax50. Together with ATM, γh2ax forms a chromatin 
complex with mediator of DNA damage checkpoint 1 (MDC1), which is also an ATM 
target51. This complex then spreads the DNA damage signal up- and downstream the 
site of DNA damage. The γh2ax marked chromatin leads to the recruitment of the Ring 
Finger proteins 8 and 168 (RNF8 and RNF168), which act as E3 ubiquitin ligases to 
mark γh2ax52. Polyubiquitinated γh2ax then acts as a scaffold for DNA repair protein 
complexes, which then promote either non-homologous end joining (NHEJ) or 
homologous recombination (HR), based on the nature of the occurred DNA damage. 
ATM is therefore not only an early detector of DNA damage, but also an important 
initiator of DNA repair. 
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Figure 2: ATM and ATR activate 
their downstream targets Chk1, 
Chk2 and p38, which either act via 
the p53-p21 axis or through 
CDC25 phosphatase mediated 
inhibition of Cyclin/Cdk complexes 
to halt the cell cycle at either the 







1.2.3. The MK2 kinase in the DNA damage response 
 
One important downstream effector of ATM and ATR is the mitogen activated protein 
kinase (MAPK) 14, commonly named p38-α, and its substrate MAPK activated protein 
kinase 2 (MAPKAPK2), or, in short, MK2. MK2 plays a pivotal role in the first 
manuscript of this dissertation and will be therefore introduced in greater detail. 
 
In their inactive state, MK2 and p38 form a nuclear localized heterodimer54. Upon 
activation, MK2 is phosphorylated by p38 at Thr33455, which triggers its nuclear export 
and function in the cytoplasm56. The p38/MK2-axis was first associated with the DDR 
when it was shown that p38 plays a role in promoting the G2/M-phase cell cycle 
checkpoint arrest by targeting Cdc25 proteins57. It has been subsequently reported 
that ATM and ATR stand upstream of p38/MK2 activation58,59. The induced G2/M-
phase cell cycle arrest has been further explained by the finding that p38/MK2 mark 
Cdc25s for 14-3-3 protein binding, thus inhibiting their nuclear translocation. In 
addition, the p38/MK2-axis stabilizes Gadd45α mRNA, while Gadd45α protein 
stabilizes p38 and its activity60. Most interestingly, MK2 has been shown to be 
responsible for the G2/M-phase cell cycle checkpoint arrest in the absence of p53, as 
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the absence of the MK2 kinase sensitizes p53-deficient tumors to cisplatin in vivo61. 
Taken together, the p38/MK2-axis controls the DDR at the G2/M-phase boundary to 
protect cellular mitosis against various genotoxic stressors. In seeming contrast, our 
group has previously described MK2 as a DNA damage inducing kinase, as 
pharmacological inhibition of MK2 relieves replicative stress upon Gemcitabine 
treatment62. Mechanistically, MK2 induces the activity of the translesion synthesis 
polymerases η and ζ, which promote DNA damage upon treatment with Gemcitabine. 
The investigation of these seemingly contrasting models of MK2 inhibition, in 
combination with Gemcitabine or cisplatin within the same biological system, is the 
main goal of the first manuscript included in this dissertation. 
 
1.3. The cell cycle 
 
1.3.1  Cell cycle regulation through Cyclins and Cdks 
 
The cell cycle phases are tightly regulated by the Cyclin and Cyclin-dependent kinase 
(Cdk) protein families63. After complexing with their corresponding Cyclin, Cdks need 
to be further phosphorylated by Cdk-activating kinases (Caks) to drive cell cycle 
progression64. Cyclin D complexes with Cdk4 and Cdk6 during the G1-phase, while 
Cyclin E functions with Cdk2 to promote S-phase entry. During DNA replication, Cyclin 
A exchanges with Cyclin E to form complexes with Cdk2, these then remain stable 
throughout the G2-phase of the cell cycle. Finally, the Cyclin A/B-Cdk1 complex drives 
the G2/M transition into mitosis64. 
 
1.3.2. Cell cycle checkpoints 
 
The Cyclin-CdK complex mediated progression of the cell cycle can be disrupted by 
the onset of DNA damage at the G1/S and G2/M cell cycle boundaries, so-called cell 
cycle checkpoints. The G1/S cell cycle checkpoint is mainly regulated by the p53 tumor 
suppressor protein65. ATM and ATR trigger the degradation of the Cdk-activating 
phosphatase Cdc25A, which inhibits DNA replication by antagonizing the Cyclin E/A-
Cdk2 complex function66. The DDR kinases also phosphorylate p53 at Ser15 and 
Ser20 directly, which activates its transcriptional activity and various downstream 
functions, such as cell cycle arrest, DNA repair and apoptosis47. One of its target 
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genes is the G1/S-Cyclin-Cdk complex inhibitor p21 alias CDKN1A, which potently 
arrests the cell cycle by binding various Cdks67. p21 has also been reported to bind 
Proliferating Cell Nuclear Antigen (PCNA), which is an integral part of DNA replication 
and repair68. The p53/p21-axis is therefore a master effector of the G1/S cell-cycle 
checkpoint, inhibiting S-phase progression by distinct mechanisms. In addition, p21 is 
able to halt the cell cycle within the S-phase by inhibiting Cdk1 and Cdk2, which is 
called the intra-S-phase checkpoint69. The second key regulator of the G/S cell cycle 
phase transition is the pRb/E2F1 complex. The Retinoblastoma tumor suppressor 
protein (pRb) is mutated in various tumors, while the name giving pathology is a rare 
cancer of the infant eye70. G1/S-Cyclin-Cdk complexes inhibit the pRb/E2F1 complex 
by phosphorylating pRb, which disrupts its binding affinity to E2F1. An unbound E2F1 
transcription factor exerts its function by promoting S-phase progression. As the 
p53/p21-axis inhibits Cyclin-Cdk function at the G1/S cell cycle boundary, pRb will not 
be in a phosphorylated state and inhibits DNA replication by restricting E2F1 
transcriptional activity47. Upon the onset of DNA damage in the G2-phase, the G2/M 
cell cycle checkpoint is activated through ATM and ATR signaling targeting the Cyclin 
A/B-Cdk1 complex71, preventing entry into mitosis. p53 also plays an important role in 
the activation of the G2/M cell cycle checkpoint, as three of its target genes, namely 
GADD45, p21 and 14-3-3σ, have been shown to inhibit the Cyclin A/B-Cdk1 complex 





Figure 3: DNA damage induced G1/S cell cycle checkpoint activation is controlled by 
p53 and pRB. pRB inhibits the E2F1 transcription factor by complex formation and 
therefore prevents S-phase entry. p53 induces the cyclin-dependent kinase inhibitor 
p21, which inhibits Cyclin E-Cdk2, leading to pRb-E2F1 complex formation. In 
addition, p21 inhibits the G2/M cell cycle transition by binding the mitosis promoting 
Cyclin A/B-Cdk1 protein complexes (modified from73). 
 
1.4. p53: The guardian of the genome 
 
1.4.1. p53 function and regulation 
 
Due to its important functions in genome maintenance and its common mutation in 
patient tumors, the p53 tumor suppressor protein has become the most studied protein 
in cancer research74. p53 is post-translationally modified by various cellular stress 
sensing pathways, which trigger its activity75. In the DDR, p53 is phosphorylated by all 
leading DNA damage kinases, namely ATM, ATR, Chk1 and Chk274. ATM and ATR 
mediated p53 activation at Ser15 disrupts its interaction with MDM2, a RING E3 
ubiquitin ligase that tightly controls p53 in the absence of cellular stressors, and thus 
stabilizes its protein levels76. MDM2 marks p53 for proteasomal degradation by 
polyubiquitination, furthermore, it masks its N-terminal transactivation domain to 
prohibit p53 transcriptional activity77. ATM is also able to phosphorylate MDM2 directly 
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at Ser395, which further disrupts the interaction with p5378. Chk1 and Chk2 
phosphorylate p53 at Ser20 to induce protein tetramerization and its transcriptional 
activity75. Once transcriptionally active, p53 activates transcription of various target 
genes, including MDM2, GADD45, p21 and the pro-apoptotic proteins, such as Bax79. 
These target genes then execute their functions in various pathways such as cell cycle 
arrest, DNA repair, senescence or apoptosis80. p53 can therefore be regarded as a 
master regulator of cell fate. 
 
1.4.2. Pharmacological stabilization of p53 and cyclotherapy 
 
MDM2 inhibitors have already been established in preclinical research81 and clinical 
trials82. One of them is Nutlin-3a, a small molecule inhibitor which antagonizes the 
p53-MDM2 protein interaction in a non-genotoxic manner83. As a result, p53 
accumulates and overdrives its pathway to promote cell cycle arrest and 
apoptosis84,85. An interesting feature of Nutlin-3a is that it activates wild-type p53 but 
does not induce similar activity when p53 is mutant. This feature gives rise to the 
concept of cyclotherapy, in which p53 wildtype cells can be protected from DNA 
damaging and mitotic chemotherapeutics by a short treatment with a tumor 
suppressor activating drug, such as Nutlin-3a, to arrest the cell cycle, whereas p53 
mutant cells will not be arrested and stay susceptible to the chemotherapeutical 
treatment86,87. The concept of cyclotherapy has been of interest in the cancer research 
community88,89,90, with evidence that it functions in vivo91,92, however there have been 
no reports of applications in patients. In this dissertation, we have combined the 
cyclotherapy approach with the concept of pretargeting, which has generated 










Figure 4: The concept of 
cyclotherapy93. p53 
proficient cells arrest their 
cell cycle upon low-dose 
p53 activator treatment, 
whereas p53 deficient cells 
do not, these then stay 
susceptible for S-phase and 
M-phase targeting drugs. 
 




The Copper catalyzed Azide-Alkyne Click (CuAAC) reaction is a highly specific 
reaction that can take place with a high fidelity within a biological system94, meaning 
that the reaction partners react with each other, but not with the naturally occurring 
biomolecules. So-called bio-orthogonal reactions have been widely applied and 
significantly contributed to molecular biological research95, as they have allowed 
researchers to specifically target and visualize cellular structures of their choice and 
interest96. A major advance in the field was the design of copper-free Click reactions, 
which, as copper is a cytotoxic agent, enabled the application of Click chemistry in 
living cells97. Researchers were now able to visualize ongoing cellular processes in 
motion. The two most important copper-free Click reactions are based on the Strain-
promoted Azide-Alkyne Click Chemistry (SPAAC)98 and the tetrazine-alkene ligation99, 
which have lead the effort to develop Click-Chemistry based clinical theranostics100. 
In this work, we have utilized a tetrazine-alkene based reaction involving the 
nucleoside analogue 5-Vinyl-2'-deoxyuridine (5-VdU)101 and a novel compound, called 
Compound B as its structure cannot yet be revealed due to patenting endeavors, 
which carries a tetrazine group and acts as a DNA-intercalator. 5-VdU surprisingly 
shows almost no cytotoxicity in cellular assays and is readily incorporated into the 
DNA by cells, making it a promising candidate for the specific targeting drug of a 
pretargeting scheme. 
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A       B 
 
 
Figure 5: Chemical structures of (A) Nutlin-3a102 and 5-Vinyl-2'-deoxyuridine (5-
VdU)103. 
 
Figure 6: Overview of Click Chemistry reactions104: (1) Copper-catalyzed Azide-Alkyne 
Click Chemistry reaction (CuAAC). (2) Copper-free Strain-promoted Azide-Alkyne 








Bio-orthogonal reactions are ideal for the concept of clinical pretargeting, in which a 
chemotherapeutic drug is divided into its specific targeting and its cytotoxic 
components105. Pretargeting allows a high dosage of the specific component and only 
needs a lower concentration of the cytotoxic component to specifically influence 
targeted cells, which results in a better cost/effect-ratio for the patient due to less side 
effects. The concept of pretargeting has already been extensively investigated in 
clinical radiotherapy research, specifically the antibody binding of a tumor-specific 
target and subsequent specific linkage of a radiolabeled small molecule through 




Figure 7: The concept of pretargeting in clinical radiotherapy research105. 
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1.6. Scope of the thesis 
 
In the first part of this dissertation we will investigate the downstream effects of MK2 
kinase inhibition on co-treatment with different classes of chemotherapeutics, namely 
cisplatin and Gemcitabine. The project serves as an example that established 
chemotherapeutic drugs can be combined with newer substances to enhance their 
potency. However, as pharmacological inhibition of MK2 leads to different outcomes 
depending on the chemotherapeutic partner, these combinatory effects are context 
related and need to be carefully tested in a preclinical setup. In a second manuscript, 
we show the design of a molecular trap, involving the pretargeting and cyclotherapy 
treatment schemes, which leads to protection of p53 wildtype and destruction of p53 
null cells. This study exemplifies the possibility to specifically mark, target and destroy 
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a b s t r a c t
The signaling pathway driven by p38 and MAPKAPK2 alias MK2 is activated as part of stress responses,
and these kinases represent attractive drug targets for cancer therapy. However, seemingly con"icting
results were obtained when assessing the role of MK2 in chemotherapy. MK2 inhibitors were reported to
either enhance or diminish the chemosensitivity of cancer cells. Here we show that this strongly depends
on the particular chemotherapeutic drug. Two different MK2 inhibitors increased the proliferating
fraction of pancreatic cancer-derived cells upon treatment with gemcitabine, whereas no consistent
protection against cisplatin was observed. Both drugs enhanced, rather than attenuated, the toxicity of
another DNA crosslinking agent, mitomycin C. Gemcitabine and cisplatin were each capable of activating
MK2, and we did not observe differences in the intracellular localization of MK2 upon treatment.
However, DNA replication fork progression, as determined by !ber assays, was restored by MK2 inhi-
bition upon treatment with gemcitabine, but not when cisplatin was used. Thus, MK2 is required for the
reduction in DNA replication in response to gemcitabine but not to cisplatin. These observations raise the
need to carefully evaluate synergisms and antagonisms with conventional chemotherapeutics when
taking MK2 inhibitors to the clinics.
© 2018 Elsevier B.V. All rights reserved.
1. Introduction
Treating cancer cells with conventional chemotherapeutics in-
terferes with the function of cellular machineries, such as those for
DNA replication and cell division. Cancer cells often undergo
various stress conditions that result from their malignant trans-
formation. The goal of chemotherapy is to exacerbate this stress to
induce cell death [1]. This is also true when treating cancers of the
exocrine pancreas. However, despite long-term efforts in clinical
investigation, this type of cancer remains among the most devas-
tating malignancies, and the best currently available chemothera-
peutic regimen only prolongs survival by a few months on average
[2].
A major stress response pathway is mediated by the p38 ki-
nases, and their best-understood downstream partner is the pro-
tein kinase MAPKAPK2, shortly known as MK2. Stresses that induce
p38/MK2 include ultraviolet irradiation, reactive oxygen species,
and also chemotherapeutics [3].
Irradiation and chemotherapy represent challenges to DNA
integrity. This is particularly obvious when treating cells with
nucleoside analogues. Gemcitabine is one of the drugs within this
class, and it is commonly used in the treatment of pancreatic cancer
[4]. It can be incorporated into the nascent DNA strands during
replication, thus making it dif!cult to continue DNA synthesis. On
the other hand, gemcitabine is an inhibitor of ribonucleotide
reductase and thereby interferes with the synthesis of the dNTPs
required for replication.
Co-treatment with platinum-based chemotherapeutics, such as
cisplatin, provides a small but measurable bene!t for pancreatic
cancer patients, compared with gemcitabine therapy alone [5].
These drugs directly cause DNA damage by crosslinking of bases,
both within (intra) and between (inter) DNA strands [6]. Inter-
strand crosslinks represent a particularly dif!cult-to-resolve alter-
ation on DNA, and their removal requires the Fanconi anemia repair
system [7]. Targeting components of this system, e. g. by inhibiting
their stabilization by heat shock protein inhibitors, represents an
opportunity of enhancing the ef!cacy of platinum-based drugs.
Accordingly, we have recently identi!ed synergistic activities of
carboplatin and an HSP90 inhibitor [8].
One particularly vulnerable phase in the cell cycle consists in S
phase. DNA damage in this phase will interfere with the* Corresponding author.
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progression of DNA replication forks, a condition commonly
referred to as replicative stress or replication stress. Enhancing
replicative stress in tumor cells represents an important strategy to
eliminate them for therapeutic purposes [9]. On the other hand, the
avoidance of replicative stress may contribute to cancer cell sur-
vival and chemoresistance. For instance, about 50% of all human
cancers retain at least one intact copy of the p53-encoding gene,
despite its tumor-suppressive activity. According to our previous
!ndings, one advantage of maintaining p53 in its wildtype state
consists in the reduction of replicative stress, both through cell
cycle arrest upon DNA damage [10e12] and also through increasing
replication processivity during S phase [13].
We have previously establishedMK2 as a mediator of replicative
stress. Speci!cally, MK2 activity is required to induce the stalling of
DNA replication forks upon treatment of cells with gemcitabine, or
with inhibitors of the checkpoint kinase Chk1. Mechanistically,
MK2 limits the activity of the translesion synthesis polymerases h
and z. A small compound (MK2 inhibitor III [14]) can be employed
to inhibit MK2. In the presence of this inhibitor, DNA replication
continues despite the presence of the chemotherapeutic nucleoside
analogue gemcitabine. Thus, intracellular signaling is a determi-
nant of tumor cell sensitivity towards this type of drugs [15,16].
MK2 was also reported to diminish Myc-driven DNA replication
through induction of microRNA 34c [17].
In seeming contrast to our results, the groups headed byM. Yaffe
and C. Reinhardt found that the absence or inhibition of MK2 can
lead to enhanced chemosensitivity. According to their data, when
p53-de!cient cells are treated with cisplatin, the absence of MK2
enhances cell death. Concerning the underlyingmechanisms, it was
proposed that MK2 phosphorylates regulators of mRNA stability,
thereby enhancing the expression of speci!c genes and providing a
block to mitotic entry before DNA repair occurs [18e20]. MK2 be-
comes essential for cell survival in this context, in particular when
wild type p53 is deleted [21]. According to this concept, MK2 in-
hibition may provide a strategy for enhancing the response of
pancreatic cancers to cisplatin.
At least at !rst glance, these !ndings seem contradictory to our
previous results. However, it should be noted that not only different
classes of chemotherapeutics were used by the two labs, but also
different cell species. We therefore compared the impact of MK2
inhibition on chemosensitivity and DNA replication, using the same
species of pancreatic cancer cells but different chemotherapeutics,
namely gemcitabine and cisplatin. Strikingly, the inhibition of MK2
had differential effects on the sensitivity of these cells towards the
two drugs. While MK2 inhibition uniformly diminished the ef!cacy
of gemcitabine, different inhibitors modulated the cytotoxicity of
cisplatin in varying directions, and the toxicity of mitomycin C was
uniformly enhanced by them. Thus, the previous observations from
the two groups can be reconciled. Mechanistically, MK2 inhibition
alleviates the impairment of DNA replication by gemcitabine, but
not when cells were treated with cisplatin. Thus, MK2 inhibition
differentially contributes to cancer cell response, depending on the
chemotherapeutic drug that the inhibitor is combined with.
2. Materials and methods
2.1. Cell culture and treatment
Panc1 and MIA PaCa-2 cells were obtained from the German
Collection of Cell lines (DSMZ, Braunschweig) and maintained in
Dulbecco's modi!ed Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and antibiotics, at 37 !C in a humidi-
!ed atmosphere with 5% CO2. For treatment, gemcitabine (Gemzar,
100 nM, Eli Lilly), cisplatin (Cisplatin KL, Neocorp), MK2 inhibitor III
(10 mM Cayman Chemical), PF3644022 (10 mM Sigma) and sorbitol
(0,4M, Roth), were diluted in pre-warmed medium and added to
the cells for the indicated periods of time.
2.2. Assessment of cell proliferation
Cells were seeded at a density of 8000 cells/well in 96-well
plates. 24 h later, the cells were treated with the drugs at the
indicated concentrations, for 24 h, and then incubated with fresh
media again. Subsequently, the percentage of cell con"uence was
determined every 24 h by bright-!eld microscopy using a Celigo
Adherent Cell Cytometer (Nexcelom). Cell proliferation was calcu-
lated from the increase in plate con"uence using the Celigo soft-
ware and evaluating three biological replica at each time point.
2.3. DNA !ber assays
DNA !ber assays to analyze replication fork progression and
origin !ring was essentially carried out as described previously
[15]. The cells were pulse-labeled with 25 mM 5-chloro-20-deoxy-
uridine (CldU) for 20min, followed by 250 mM 5-iodo-20-deoxyur-
idine (IdU; both from Sigma-Aldrich) for 1 or 2 h, along with
treatment by gemcitabine and/or inhibitor as indicated. Cisplatin
pretreatment was carried out for 24 h. The cells were harvested,
and DNA !bers were spread on glass slides. After acid treatment,
CldU- and IdU-labeled tracts were detected by 1 h incubation at
37 !C with rat anti-BrdU antibody (dilution 1:500 detects BrdU and
CldU; AbD Serotec) and mouse anti-BrdU antibody (1:500, detects
BrdU and IdU; Becton Dickinson). Slides were !xed in 4% para-
formaldehyde/PBS and incubated for 2 h at room temperature with
Alexa Fluor 555-conjugated goat anti-rat antibody (dilution 1:250)
or Alexa Fluor 488-conjugated goat anti-mouse antibody (dilution
1:250; both from Molecular Probes/Thermo!sher). Samples were
mounted in Vectashield (Vector Laboratories). Fiber images were
acquired by "uorescence microscopy. The lengths of CldU- (red)
and IdU- (green) labeled !bers were measured by using the Fiji
software in pixels, converted to micrometers and subsequently
converted to kb using the conversion factor 1 mm" 2.59 kb. Repli-
cation structures were quanti!ed by using the Cell Counter Plug-in
for Fiji (Kurt De Vos, University of Shef!eld, Shef!eld, United
Kingdom).
2.4. Immunoblot analysis
Cells were harvested in protein lysis buffer (20mM TRIS-HCl pH
7.5, 150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1mM beta-
glycerophosphate, 2M urea, protease inhibitor cocktail, Roche).
After 10min lysis on ice, the samples were brie"y sonicated to
disrupt DNA-protein complexes. Total protein concentration was
measured using a Pierce BCA Protein assay kit (Thermo Scienti!c
Fisher). After boiling the samples in Laemmli buffer at 95 !C for
5min, equal amounts of protein samples were separated by SDS-
PAGE, transferred onto nitrocellulose, and visualized with the
following antibodies, followed by peroxidase-coupled secondary
antibodies and chemiluminescence: Phospho-MAPKAPK-2
(Thr334) (3007, Cell Signaling), Phospho-Hsp27 (Ser82) (2401,
Cell Signaling), MAPKAPK-2 (MK2) (3042, Cell Signaling), Hsp27
(2402, Cell Signaling), beta-Actin (ab8227 Abcam), Phospho-KAP1
(Ser824) (ab70369, Abcam).
2.5. Flow cytometry
For cell cycle analysis, cells were !xed in ethanol and washed
with 0.05% Triton-X in PBS. Subsequently, the cells were resus-
pended in 1mg/ml RNAse A solution in PBS and incubated for
30min at 37 !C, and then with propidium iodide (!nal
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concentration: 30 mg/ml). Flow cytometry was performed using the
Guava PCA-96 Base System (Millipore), and the distribution of DNA
contents was determined using the Guava Express Pro software.
2.6. Plasmid construction and establishment of stable cell lines
U2OS cells were transfected with expression plasmids and
selected with neomycin to obtain stable integrates. MK2-myc
expression was veri!ed by immuno"uorescence analysis. A poly-
clonal U2OS cell line stably expressingMyc-MK2WTwas generated
by transfection with the vector pIRESneo Myc-MK2 WT. To
generate a control cell line, U2OS cells were transfected with the
empty vector pIRESneo. pIRESneo encodes neomycin-resistance.
Cells that integrated the construct into their genome were
selected with 500 mg/ml geneticin.
2.7. Immuno"uorescence analysis
Upon !xation (4% paraformaldehyde, 20min) and per-
meabilization (0.2% Triton X 100, 30min), the cells were blocked
with 10% FCS in PBS, and incubated with primary antibodies to the
myc tag, clone 4A6, 1:200 (CA92590, Upstate) and a secondary
antibody labeled with AlexaFluor488 goat anti-mouse (A-11029,
Molecular Probes). Images were obtained by "uorescent micro-
scopy Zeiss Axioscope A1, ZEN 2 software.
3. Results
3.1. MK2 inhibition confers protection of cells speci!cally towards
gemcitabine
To directly compare the impact of MK2 inhibition on chemo-
sensitivity, we treated Panc1 cells (pancreatic ductal epithelial
carcinoma, carrying the p53 mutation R273H and the K Ras mu-
tation 12D [22]) with gemcitabine or cisplatin, at different con-
centrations. In addition, the cells were treated with an inhibitor of
MK2 or control-treated. After replacing all drugs with fresh media,
we followed the capability of the surviving cells to grow into
con"uence over several days, as monitored by translucent micro-
scopy and quantitative image evaluation (Celigo). In the presence of
gemcitabine, cell growth was rescued by the MK2 inhibitor III
(Fig. 1A), as we had observed previously [15,16]. In contrast, how-
ever, the MK2 inhibitor III enhanced the cytotoxic activity of
cisplatin (Fig. 1B). Thus, when cells were co-treated with MK2 in-
hibitor III and cisplatin, far less cells retained the capability of
proliferationwhen compared to the individual treatment with each
drug. Analogous observations were made with MIA PaCa-2 cells (K-
Ras 12C, p53 248W [22]; Fig. 1C and D). Thus, MK2 inhibitor III
affects the sensitivity of cells towards each drug in opposite di-
rections. It confers resistance towards gemcitabine, in agreement
with our previous !ndings [15,16], but it also sensitizes the same
p53-mutant cells towards cisplatin, in agreement with the reports
from the Yaffe lab [18,20,21]. Using a different MK2 inhibitor, PF-
3644022 [23], reproduced the results obtained with gemcitabine
in the MIA PaCa-2 cell line. Like MK2 inhibitor III, PF-3644022
profoundly reduced the toxicity of gemcitabine, further corrobo-
rating the notion that MK2 is a key mediator for the cytotoxic effect
of gemcitabine (Fig. 1E). Interestingly, cell survival was differen-
tially affected by the two MK2 inhibitors, as revealed by co-
treatment with cisplatin and PF-3644022 (Fig. 1F). In contrast to
MK2 inhibitor III (Fig. 1D), PF-3644022 enhanced the survival of
cisplatin-treated cells to some extent, perhaps due to additional
targets of the two drugs [24]. To test the impact of MK2 inhibitors
on the ef!cacy of another DNA crosslinking agent, we treated the
cells with mitomycin-c (MMC), with and without MK2 inhibitors,
and followed cell survival by quantitativemicroscopy (Fig.1G). Both
MK2 inhibitor III as well as PF-3644022 decreased cell survival
uponMMC treatment, in contrast to their pro-survival effects when
combined with gemcitabine. We conclude that MK2 appears as a
survival factor, rather than a mediator of cytotoxicity, in the pres-
ence of the DNA-cross-linker MMC.
3.2. Gemcitabine and cisplatin are each capable of inducing MK2
activity
Besides the classical DNA damage responsive signaling path-
ways driven by ATM/Chk2 and ATR/Chk1, chemotherapeutics also
induce stress signaling through the p38 kinases and MK2, as we
have previously reported for gemcitabine [15,16]. To test whether
the same is true for cisplatin, we incubated MIA PaCa-2 cells with
each drug, followed by immunoblot detection of phosphorylated
Hsp27, a bona !de substrate of MK2 [25]. Cisplatin and gemcitabine
each induced Hsp27 phosphorylation to comparable extents and
with comparable kinetics (Fig. 2A). Hsp27 phosphorylation was
strongly diminished by MK2 inhibition (quanti!ed in Fig. S1),
indicating that it was indeed re"ecting MK2 activation. The same
effect was observed using the MK2 inhibitor PF3644022 (Fig. 2B).
Thus, both gemcitabine and cisplatin are comparable activators of
MK2. Moreover, both drugs increased the phosphorylation of Kap1
(Fig. 2C), a substrate of ATM [26], with cisplatin having a stronger
impact. Of note, the MK2 inhibitor III somewhat increased
cisplatin-induced Kap1 phosphorylation, while gemcitabine-
mediated Kap1 phosphorylation was reduced by MK2 inhibition.
Thus, the differential effect of MK2 inhibition on cell proliferation
(Fig. 1) was re"ected by the phosphorylation of Kap1 (Fig. 2C),
arguing that ATM activity and thus the DNA damage response is
aggravated by MK2 inhibition in the case of cisplatin, but attenu-
ated upon gemcitabine treatment.
3.3. Neither gemcitabine nor cisplatin detectably affect the
intracellular location of MK2
It was previously proposed that MK2 displays a cytoplasmic
activity to stabilize Gadd45alpha, thus providing a protective
checkpoint [20]. We therefore tested whether cisplatin or gemci-
tabine might change the intracellular location of MK2. First, we
generated a cell line that stably expresses MK2with an immunotag,
thus enabling the detection of MK2 by immuno"uorescence
(endogenous MK2 levels were insuf!cient for detection by this
method). MK2 was mostly found in the nucleus with some addi-
tional cytoplasmic staining (Fig. 3, quanti!ed in Fig. S2A). However,
we did not observe a change in this staining pattern when treating
the cells with either cisplatin or gemcitabine. In contrast, incuba-
tion of the cells with the osmotic stressor sorbitol led to a mostly
cytoplasmic location of MK2, in accordance with a previous report
[27]. However, co-treatment with gemcitabine or cisplatin did not
affect this distribution when compared to sorbitol alone, arguing
that the drugs do not actively promote nuclear import of MK2
either. Neither did treatment with MK2 inhibitor affect the location
of MK2, arguing that the activity of MK2 does not change its
intracellular transport. We have further compared the phosphor-
ylation ofMK2 (and also the phosphorylation of its substrate HSP27,
Fig. S2B) upon treatment with sorbitol vs. gemcitabine and
cisplatin. Here, sorbitol showed by far the strongest activation of
MK2. This might well be the reason why MK2 export was observed
only with sorbitol. We conclude that, while MK2 is an important
determinant of cellular responses to chemotherapy, its basal ac-
tivity seems suf!cient for this, without the need for strong activa-
tion, phosphorylation and export of MK2. We further conclude that
a differential role of MK2 in the ef!cacy of the two drugs cannot be
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explained by drug-induced differences in intracellular MK2
location.
3.4. DNA replication fork progression is enhanced by MK2
inhibition in the presence of gemcitabine but not cisplatin
To understand the differential sensitivity of MK2-inhibitor-
treated cells towards the two chemotherapeutics, we now explored
the characteristics of DNA replication under each condition. First,
we assessed the distribution of DNA content upon treatment of an
asynchronous MIA PaCa-2 cell population with either gemcitabine
or cisplatin for 48 h (Fig. 4A). In the case of gemcitabine, most cells
accumulated with a DNA content between 2n and 4n, indicative of
an arrest in S phase. In contrast, a large proportion of the cisplatin-
treated cells were found with a DNA content near 4n, arguing that
they still go through S but arrest at G2/M. These notions were
con!rmed by quantitation of the cell cycle pro!les. Thus, DNA
replication is impaired by gemcitabine but only to a lesser extent by
cisplatin.
To further address the impact of MK2 on DNA replication, DNA
!ber assays were performed by incubating the pretreated cells with
nucleosides that carry halogen substitutions in their bases. Upon
incorporation of these nucleosides, newly synthesized DNA be-
comes detectable by antibodies. Subsequently, the cells were
Fig. 1. MK2 inhibition protects pancreatic cancer cells against gemcitabine but sensitizes against cisplatin.
A. Panc1 cells were seeded at a con"uency of 20% and treated with gemcitabine (75 nM) and/or MK2 inhibitor III (10 mM) for 24 h. After removing the drugs by changing the media,
cell con"uence was monitored daily by bright !eld microscopy with quantitative image analysis (Celigo, Nexcelom) for 12 days. The results from three parallel experiments are
shown as mean and SEM (note that the error bars are sometimes too small to be seen immediately). The number of proliferating cells was increased when gemcitabine was
combined with MK2 inhibitor III, as compared to the treatment with gemcitabine alone. B. Panc1 cells were treated and monitored as in A, but with cisplatin (0.5 mM) instead of
gemcitabine. Here, the combination of MK2 inhibitor with cisplatin led to a profound decrease in cell con"uency, as compared to either drug alone. C. As in A, but using MIA PaCa-
2 cells, with similar results as for Panc1 cells. D. As in B, with MIA PaCa-2 cells, but treated with 5 mM cisplatin instead of 0,5 mM, again obtaining similar results as with Panc1 cells. E.
As in C, but using PF3644022 and treated with 50 nM gemcitabine instead of 75 nM, with similar results as for MK2 inhibitor III. F. As in D, but using PF3644022, the number of
proliferating cells was increased when cisplatin was combined with PF3644022, as compared to the treatment with cisplatin alone. G. MIA PaCa-2 cells were treated and monitored
as in A, but with mitomycin c (MMC) instead of gemcitabine. Here, the combination of MK2 inhibitor III or PF3644022 with MMC led to a decrease in cell con"uency, as compared to
either drug alone.
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harvested and their DNA was spread on glass slides, followed by
"uorescent detection of DNA that was synthesized during the la-
beling period. The length of labeled tracks on DNA !bers allowed us
to determine the average speed by that replication forks moved
along their template (Fig. 4B). As shown previously in other cell
species [15], we found that gemcitabine reduced fork progression
in pancreatic cancer cells. However, this was partially rescued by
the addition of MK2 inhibitor (Fig. 4, B-E, Suppl. Fig. S3A and
Suppl. Table S1), consistent with our previous results and pointing
to a chemoprotective effect of MK2 inhibition [15,16]. Like MK2
inhibitor III, PF-3644022 enhanced DNA replication fork progres-
sion in the presence of gemcitabine (Fig. 4, F-G, Suppl. Fig. S3D and
Suppl. Table S2).
Next we tested whether the same holds true in cisplatin-treated
cells. Firstly, we found that only high amounts of cisplatin (10 mM
but not 5 mM for MK2 inhibitor III, and 50 mM for PF3644022) for
24 h compromised DNA replication to an extent that could be
readily observed by DNA !ber assays (Suppl. Fig. S3, cf. B and C). To
explain this, it should be noted that commonly used amounts of
cisplatin cause relatively few DNA interstrand crosslinks within the
genome, roughly 1000 per cell when using 1 mM cisplatin [28] on a
total DNA content of 2# 3# 109 bases. We assume that DNA
replication at these few sites is virtually impossible, since DNA
strands cannot be separated there. However, the majority of DNA
regions appear to remain in a state that allows unperturbed repli-
cation. Based on these considerations, we were using high con-
centrations of cisplatin (10 mM) for 24 h and indeed observed
impaired DNA replication by reduced track length in !ber assays.
Importantly, however, this reduction in fork progression was not
ameliorated by MK2 inhibitor III (Fig. 5, A-D, Suppl. Fig. S3C and
Suppl. Table S1) nor by PF3644022 (Fig. 5, E-F, Suppl. Fig. S3E and
Suppl. Table S2).
We conclude that the protective effect of MK2 inhibitors on the
processivity of DNA replication applies to a nucleoside analogue but
not to a DNA-crosslinking agent such as cisplatin.
4. Discussion
Our results clarify the differential response of cancer cells to
combinations of chemotherapy with MK2 inhibition. Rather than
Fig. 2. MK2 activation by cisplatin as well as gemcitabine but differential impact of MK2 on the DNA damage response.
A. MIA PaCa-2 cells were treated with cisplatin (10 mM) or gemcitabine (100 nM) for the indicated periods of time. MK2 activity was assessed by detecting phosphorylated Hsp27, a
bona !de MK2 substrate. In each case, one sample was treated with MK2 inhibitor, thus ensuring that Hsp27 phosphorylation truly re"ects MK2 activity. pHsp27, phosphorylated
Hsp27 (Ser82); tHsp27, total Hsp27. B. As in A, but using PF3644022, with similar results as for MK2 inhibitor III. C. Upon treatment as above for 24 h, phosphorylated Kap1 (Ser824)
was detected to re"ect ATM activity [26]. Total MK2 (tMK2; regardless of modi!cations) was visualized as well, in addition to Actin (loading control). The experiment was conducted
thrice, n" 3.
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contradicting each other, the previously published results on such
combinations are compatible. MK2 inhibition can sensitize or
protect cancer cells of the same species, depending on the
chemotherapeutic drug that the inhibitor is combined with. MK2
inhibition alleviates replicative stress imposed by a nucleoside
analogue, gemcitabine but not when combined with cisplatin.
Inhibitors of MK2 represent promising candidates for clinically
improving cancer treatment. Mice with a targeted disruption of the
gene encoding MK2 are viable [29], strongly suggesting that spe-
ci!c MK2 inhibitors should have acceptable toxicities to a patient.
Fig. 3. Lack of change in MK2 location upon treatment with cisplatin or gemcitabine.
Myc-tagged MK2 was stably expressed in U2OS cells, followed by treatment as indicated for 4 h . Immunodetection of MK2 through the myc-tag revealed that none of the
chemotherapeutic drugs nor the inhibitor of MK2 induced cytoplasmic accumulation of MK2. In contrast, sorbitol was capable of inducing a shift in MK2 location from the nucleus
to the cytoplasm, as described previously [27]. However, the combination of sorbitol with chemotherapeutics or MK2 inhibitor did not induce detectable changes in localization, as
compared to sorbitol alone.
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Fig. 4. Restored DNA replication by MK2 inhibition in the presence of gemcitabine.
A. Distribution of DNA content upon drug treatment. While gemcitabine treatment led to accumulation of cells with a DNA content between 2n and 4n, cisplatin increased the
proportion of cells with a DNA content near 4n. Quanti!cation was achieved using the Guava analysis software from three independent datasets. B. Treatment scheme for DNA !ber
assays. Panc1 cells were pre-treated with 10 mM MK2 inhibitor III for 1 h and then further incubated with the same inhibitor concentration. The cells were then also exposed to the
nucleoside analogues CldU (25 mM, 20min) and IdU (250 mM, 2 h) to label newly synthesized DNA. During the IdU label, gemcitabine was added at 500 nM. The cells were then
harvested, their DNAwas spread on glass slides, and the newly synthesized DNAwas stained by antibodies to CldU and IdU. C. Representative images obtained by !ber analysis. The red
label corresponds to CldU incorporation, the green label to IdU. D. The length of the labeled tracks was determined. Their mean and SEM is displayed in the columns. Raw data and
replica are provided in Suppl. Fig. S1 and Suppl. Table 1. Note that DNA replication is suppressed by gemcitabine, but that MK2 inhibition partially rescues the fork rates. ***, p < 0.0001.
E. Distribution of replication fork speeds. The labeled tracks were classi!ed to histograms, re"ecting the number of forks with a speed between the indicated numbers (kb/min) and the
next 0.1 digit. The percentage of tracks within each class is displayed by the columns. F. As in D, but in MIA PaCa-2 cells and additionally incorporating PF3644022 into the drug panel,
with similar results. G. Evaluation as in E. (For interpretation of the references to colour in this !gure legend, the reader is referred to the Web version of this article.)
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The same holds true for mice that lack both MK2 and MK3 [30],
raising the possibility that even inhibitors of both kinases should be
tolerable. However, our results make it clear that care must be
taken when choosing the particular chemotherapeutic drug to
combine with MK2 inhibitors. This raises the question which drugs
will cooperate with MK2 inhibitors, and in which cases the drugs
will antagonize each other. Cooperation for increased cytotoxicity
was reported for cisplatin, but also for the topoisomerase II
inhibitor doxorubicin [18,20]. Moreover, MK2 can mediate resis-
tance to gamma irradiation by phosphorylating ATDC/TRIM29 [31].
MK2 also confers resistance to oxidative stress [32]. These effects
might be overcome by MK2 inhibition, leading to synergistic
cytotoxicity. On the other hand, we have previously observed
cytoprotection by MK2 inhibitors during treatment with gemcita-
bine [15,16], ultraviolet irradiation [15], and treatment with a Chk1
inhibitor [15]. Thus, it appears that drugs and DNA damage that
Fig. 5. Compromised DNA replication by high concentrations of cisplatin, but independent of MK2 inhibition.
A. Treatment scheme for DNA !ber assays. To observe diminished DNA replication, Panc1 cells were pre-treated for 24 h with 10 mM cisplatin, with or without 10 mM MK2 inhibitor
III. The cells were then further incubated with the same drugs and simultaneously exposed to the nucleoside analogues CldU (20min) and IdU (1 h). Tracks of newly synthesized
DNA were then visualized by antibody staining. B. Images of labeled tracks. C. Summary of the track lengths corresponding to replication fork progression. The numbers below the
columns indicate the number of tracks evaluated in each case. For replica and raw data, cf. Suppl. Fig. S1 and Suppl. Table 1. It was observed that DNA replication is suppressed by
10 mM cisplatin, without rescue by MK2 inhibition. D. Distribution of replication fork speeds. The labeled tracks from D were classi!ed to histograms as in Fig. 4E. E. As in C, but in
MIA PaCa-2 cells and additionally incorporating PF3644022 into the drug panel, with similar results using 50 mM instead of 10 mM cisplatin. F. Evaluation as in D.
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mostly interfere with DNA replication can be antagonized by MK2
inhibition, whereas other drugs can cooperate with the MK2 in-
hibitors. However, in the case of topoisomerase inhibitors, this
distinction is dif!cult to make in a sharp manner, since top-
oisomerases are essential during DNA replication but also required
for DNA integrity during other phases of the cell cycle [33].
When combining Chk1 inhibitors with MK2 inhibitors, another
interesting difference arises with respect to the tumor genotype. It
was reported that tumor cells with a KRAS mutation speci!cally
lose viability in response to the simultaneous inhibition of both
kinases [34]; this is in contrast to our observations in U2OS cells,
where the two drugs antagonize each other [15]. Thus, and perhaps
not surprisingly, the tumor cell genotype also needs to be taken into
account when evaluating these drug combinations.
Additional reasons for differential sensitization of cancer cells
towards chemotherapeutics may also consist in the speci!c re-
quirements of DNA repair machineries. For gemcitabine, we have
previously found that translesion synthesis polymerases contribute
to resistance in an MK2-dependent manner [15]. In the case of
cisplatin, however, the Fanconi anemia pathway is of particular
importance for repair, and its targeting by HSP90 inhibition sensi-
tizes cancer cells towards platinum compounds [8]. Thus, MK2
activity may affect different repair mechanisms in different ways.
Most other chemotherapeutics have not been evaluated in
combination with MK2 inhibitors. Since accurate predictions are
dif!cult, we propose that any other cytotoxic drug needs to be
carefully tested as to its cooperation or antagonism with MK2 in-
hibitors, before taking such drug combinations to the clinics.
Mechanistically, the impact of such drugs on DNA replication may
serve as a guideline for such evaluations.
If MK2 inhibitors can be tolerated by the body, why would
cancer cells respond by cell death, evenwhen cisplatin is applied in
addition? It was proposed that the absence of the tumor suppressor
p53 determines the response of cells towards the combination [18].
Indeed, the cells that were employed in the present study lack wild
type p53, thereby re"ecting the majority of pancreatic carcinomas.
It is very possible that the absence of functional p53 forti!es the
response observed in our study. For instance, p53 is known to
promote the expression of the phosphatase DUSP1/MKP1, an
antagonist to p38 signaling [35]. Active p53 may also suppress the
accumulation of reactive oxygen species [36]. Thus, the combina-
tion of MK2 inhibitor and platinum drugs conceivably takes
advantage of a therapeutic window set up by themutation of p53 in
tumor cells.
Inhibitors of p38 are already in clinical trials. For instance,
LY2228820 is being tested according to clinicaltrials.gov with the
IDs: NCT02322853, NCT02364206, NCT01663857, NCT01393990,
NCT02860780. MK2 inhibitors are in preclinical development [24].
Despite the strong potential of these compounds as chemo-
sensitizers, their use in combination therapies requires pre-
evaluation with each particular chemotherapeutic drug to achieve
synergisms rather than negative interference.
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3.1. A two-step bio-orthogonal reaction enables specific targeting of p53-
mutant cells via Nutlin-3a mediated protection of p53-wildtype cells 
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Abstract:  
Over 50% of all cancers carry a mutation in the p53 tumor suppressor gene, yet no 
chemotherapeutic drug specifically targeting this group of mutations is established in 
the clinical routine. One approach to exploit p53 mutations consists in the concept of 
cyclotherapy. Accordingly, a low dose of a p53 activator arrests the cell cycle in all 
non-transformed cells of the organism, whereas the p53-mutated cancer cells remain 
sensitive to chemotherapeutics active in S-phase and mitosis. Here, we have 
combined cyclotherapy with a pretargeting approach, meaning the temporal 
uncoupling of a target-specific compound from its cytotoxic component. In our 
strategy, pretargeting comprises a bio-orthogonal reaction between the nucleoside 
analogue 5-Vinyl-2'-deoxyuridine (5-VdU) and a genotoxic partner molecule, 
compound B, via the tetrazine-alkene ligation reaction. In our setup, this reaction 
specifically targets p53 mutated cells, since pre-treatment with the MDM2 antagonist 
Nutlin-3a activated p53 and thus prevented the incorporation of 5-VdU into DNA. The 
combination of 5-VdU and compound B induced DNA damage and profoundly 
interfered with the proliferation of cultured cells. Moreover, it reduced the progression 
of DNA replication forks and arrested cells in mitosis. Pre-treatment with Nutlin 
prevented the toxicity of 5-VdU and compound B in p53-proficient cells. Taken 
together, the bio-orthogonal combination of 5-VdU and compound B presents itself as 
a powerful combination to treat p53 mutated cancer cells in a pretargeting approach, 
whereas p53 activation enables cyclotherapy and thus specificity to this strategy. Put 
in a bigger picture, pretargeting with nucleosides, which at the same time act as bio-




The transcription factor p53 is mutated in over 50% of all cancers, making it the most 
important tumor suppressor protein and a therapeutic target for human malignant 
disease of the highest priority106,107. Cellular stressors, such as DNA damage, trigger 
stabilization and activation of p53, which lead to gene expression to promote cell cycle 
arrest, DNA repair and ultimately apoptosis107. The levels of p53 protein in the cell are 
controlled by the E3 ubiquitin ligase MDM2 through a negative feedback loop. MDM2 
is a transcriptional target of p53 and promotes its proteasomal degradation through 
ubiquitination108. The chemical inhibition of MDM2 stabilizes the p53 protein and 
promotes cell cycle arrest and apoptosis. Such inhibitors have been already implicated 
in preclinical research81 and clinical trials82,109, however they have not yet been 
approved for the clinical routine. Adverse effects of MDM2 small molecule antagonists 
include gastrointestinal and hematological toxicity, with the most severe being 
neutropenia and thrombocytopenia110. Another way to utilize these p53 stabilizing 
compounds is the concept of cyclotherapy, in which only a low dosage of the drug is 
administered for a short term to arrest the cell cycle in non-cancerous cells of the 
patient, this protects them from chemotherapeutics that act during replication or 
mitosis, and allows specific targeting of p53 mutant cells93. The low dose regimen 
would also decrease the onset of adverse effects of p53 activating drugs110. 
 
The “Click-Chemistry” is a highly specific reaction, which was originally designed as 
the Copper catalyzed Azide-Alkyne Click (CuAAC) reaction94. Such bio-orthogonal 
reactions, meaning artificially introduced compounds specifically react with each other 
and not with naturally occurring cellular molecules, have been widely applied in 
biomedical research95, in which they have enabled researchers to study specific 
macromolecules in situ96. As copper is cytotoxic, live cell applications were only made 
possible through the discovery of copper-free bioconjugations97, most importantly the 
Strain-promoted Azide-Alkyne Click Chemistry (SPAAC) reaction98 and the tetrazine-
alkene ligation99. They have led to the endeavor to develop bio-orthogonal reactions 
in clinical diagnostics and tumor targeted therapy100. Bio-orthogonal reactions can also 
be utilized for the concept of pretargeting, which uncouples the targeting compound 
from the cytotoxic agent to enhance their therapeutic index, meaning the ratio of drug 
toxicities to drug therapeutic effects105. In addition, researchers have successfully 
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generated copper free clickable nucleosides, i.e. nucleoside analogues, to target live 
cell DNA for diagnostics111,112,113,101 and therapy114. Copper dependent clickable 
nucleosides, notably Bromodesoxyuridine (BrdU) and 5-Ethynyl-2'-deoxyuridine 
(EdU), have already been widely applied for DNA research115. Copper free nucleoside-
analogues include 5-Vinyl-2'-deoxyuridine (5-VdU)101, 5-(Azidomethyl)-2′-
deoxyuridine (AmdU)111 and its enhanced version 5′-bispivaloyloxymethyl (POM)-
AmdU112,114, both substances visualize DNA in living cells, while POM-AmdU is able 
to generate toxic DNA-DNA interstrand crosslinks (ICL) reacting with the Sondheimer 
diyne derivative DiMOC114 and can visualize nuclei in vivo112 (Danio rerio). The in vivo 
activity and the potential use in pretargeting render these novel compounds potential 
candidates for drug discovery. 
 
In this manuscript, we present the synergistic cytotoxic effects of a novel bio-
orthogonal compound (compound B) in cultured cells. It acts as a DNA intercalator, 
within a previously described tetrazine-alkene ligation reaction111 with the nucleoside 
analogue 5-VdU. We further incorporated the strong cytotoxic effects of the chemical 
combination of 5-VdU and compound B within a cyclotherapy approach. Dependent 
on the p53 mutation status, Nutlin-3a acted cytoprotective against the combination. In 
conclusion, this treatment scheme, once applied in vivo, would allow specific targeting 
of tumor suppressor mutated cancers, while protecting the non-transformed cells of 
the host.  
 
3.2. Materials and Methods 
3.2.1 Cell culture and treatment  
H1299 and HCT116 p53 +/+ and HCT116 p53 -/- cells were obtained from the German 
Collection of Cell lines (DSMZ, Braunschweig), mouse pancreatic cancer cells (KPC) 
were a kind gift of Dr. Elisabeth Hessmann. The cultures were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), L-Arginine and antibiotics, at 37°C in a humidified atmosphere with 5% 
CO2. For treatment, 5-VdU and compound B (both synthesized in Nathan Luedtke 
lab) or Nutlin-3a (Sigma), were diluted in pre-warmed medium and added to the cells 
for the indicated periods of time.  
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3.2.2 Assessment of cell proliferation  
Cells were seeded at a density of 5000 cells/well in 96-well plates. 24 h later, the cells 
were treated with the drugs at the indicated concentrations, for 24 h, and then 
incubated with another drug for 24 h or with fresh media again. Subsequently, the 
percentage of cell confluence was determined every 24 h by bright-field microscopy 
using a Celigo Adherent Cell Cytometer (Nexcelom). Media was exchanged every 48 
h. Cell proliferation was calculated from the increase in plate confluence using the 
Celigo software and evaluating three biological replicates at each time point.  
3.2.3 DNA fiber assays  
DNA fiber assays to analyze replication fork progression was essentially carried out 
as described previously62. The cells were treated with 5-VdU for 24 h and then with 
compound B for 24 h. They were then pulse-labeled with 25 μM 5-chloro- 2′-
deoxyuridine (CldU) for 20 min, followed by 250 μM 5-iodo-2′-deoxyuridine (IdU; both 
from Sigma-Aldrich) for 1 h. The cells were harvested, and DNA fibers were spread 
on glass slides. After hydrochloric acid treatment, CldU- and IdU-labeled tracts were 
detected by 1 h incubation at 37 °C with rat anti-BrdU antibody (dilution 1:500 detects 
BrdU and CldU; AbD Serotec) and mouse anti-BrdU antibody (1:500, detects BrdU 
and IdU; Becton Dickinson). Slides were fixed in 4% paraformaldehyde/PBS and 
incubated for 2 h at room temperature with Alexa Fluor 555-conjugated goat anti-rat 
antibody (dilution 1:250) or Alexa Fluor 488-conjugated goat anti-mouse antibody 
(dilution 1:250; both from Molecular Probes/Thermofisher). Samples were mounted in 
Vectashield (Vector Laboratories). Fiber images were acquired by fluorescence 
microscopy. The lengths of CldU- (red) and IdU- (green) labeled fibers were measured 
by using the Fiji software in pixels, converted to micrometers and subsequently 
converted to kb using the conversion factor 1μm = 2.59 kb. Replication structures were 
quantified by using the Cell Counter Plug-in for Fiji (Kurt De Vos, University of 




3.2.4 Immunoblot analysis  
Cells were harvested in protein lysis buffer (20mM TRIS-HCl pH 7.5, 150mM NaCl, 
1mM Na2EDTA, 1mM EGTA, 1mM beta-glycerophosphate, 2M urea, protease 
inhibitor cocktail, Roche). After 10min lysis on ice, the samples were briefly sonicated 
to disrupt DNA-protein complexes. Total protein concentration was measured using a 
Pierce BCA Protein assay kit (Thermo Scientific Fisher). After boiling the samples in 
Laemmli buffer at 95°C for 5min, equal amounts of protein samples were separated 
by SDS-PAGE, transferred onto nitrocellulose, and visualized with the following 
antibodies, followed by peroxidase-coupled secondary antibodies and 
chemiluminescence: phosphorylated Ser 139 H2AX (05-636, Millipore), 
phosphorylated Ser 317 Chk1 (2344, Cell Signaling Technology), PARP1 (9542, Cell 
Signaling Technology), beta-Actin (ab8227 Abcam), Ser 10 H3 (D2C8-XP, Cell 
Signaling Technology). 
3.2.5 Flow cytometry  
For cell cycle analysis, cells were fixed in ethanol and washed with 0.05% Triton-X in 
PBS. Subsequently, the cells were resuspended in 1mg/ml RNAse A solution in PBS 
and incubated for 30 min at 37°C, and then with propidium iodide (final concentration: 
30 μg/ml). Flow cytometry was performed using the Guava PCA-96 Base System 
(Millipore), and the distribution of DNA contents was determined using the Guava 
Express Pro software.  
3.2.6 Fluorescence microscopy 
Pretreated cells in 8 chamber slide wells (nunc labtek, 177445) were incubated with 
Hoechst DNA stain (Thermo Fisher Scientific) at a concentration of 2 μg/ml for 15 mins 
and then mounted in PBS for microscopy. Images were obtained by fluorescent 









3.3.1 The combination of 5-VdU and compound B exhibits synergistic lethality 
in human and mouse cancer cell lines 
 
To evaluate a possible synergistic effect between 5-VdU and compound B, we treated 
H1299 cells, a human non-small cell lung carcinoma (NSCLC) cell line, and cells of 
the murine KPC model, which is K-Ras and p53 mutated and contains a pancreas-
specific promoter to express the Cre-recombinase116, with the indicated drugs. Cells 
were treated with 5-VdU for 24 h and subsequently 24 h with compound B (see Fig. 
8E). They were then either further observed with live cell confluency measurements 
or lysed for Western Blot analysis. Both H1299 cells (Fig. 8A & 8C) and KPC cells 
(Fig. 8B and 8D) exhibited a strong synergistic effect upon the combination of 5-VdU 
and compound B. Cell viability was drastically decreased in the cell confluency assays 
upon treatment with the combination, whereas 5-VdU or compound B alone exhibited 
almost no toxicities by themselves (Fig. 8A & B). In the Western Blot analyses a strong 
amplification of the DNA damage marker yH2AX was detected upon treatment with 
the combination, while 5-VdU and compound B only lead to a small increase when 
compared with the DMSO control (Fig. 8C and 8D). Furthermore, the activating 
phosphorylation of the DNA damage sensor kinase Chk1 on Ser317 was increased in 
H1299 cells upon treatment with the combination when compared to the single drugs 
alone (Fig. 8C). In KPC cells the cleavage of the apoptosis marker PARP was 
augmented in the combination (Fig. 8D), implying an activation of the apoptotic 
pathway. Taken together, the combination of 5-VdU and compound B acts 
synergistically to decrease cell viability in a live cell confluency assay and activates 











Figure 8: Synergistic lethality of 5-VdU and compound B. Cell confluency upon 
treatment with the drugs was measured daily using (A) H1299 cells and (B) 
mouse KPC cells. Western Blot analysis reveals synergistic effects of 5-VdU 
and compound B on markers of DNA damage and cell death (C) H1299 cells 













3.3.2. 5-VdU is incorporated into the cellular DNA, binds compound B and can 
be visualized in live cells 
 
To rule out DNA independent effects of the combination of 5-VdU and compound B, 
we have used fluorescence microscopy to visualize compound B, which is supposed 
to be excitable at 555nm. Live cell nuclei can be imaged using the Hoechst 33342 
stain117. Cultured H1299 cells were treated with 5-VdU for 24 h and subsequently with 
compound B for 24 h, treated with Hoechst stain and then directly mounted for 
fluorescence microscopy (Fig. 9B). And indeed, compound B can be imaged at the 
indicated wavelength and the signal colocalizes with the Hoechst nuclear stain (Fig. 
9A). This result suggests, that the cytotoxic and DNA damaging effects of the 
combination of 5-VdU and compound B are due to specific interaction of the two drugs 
at the cellular DNA and not elsewhere in the cell. 
 
Figure 9: (A) Nuclear localization of the compound B signal shown by co-localization 
with the Hoechst nuclear stain in living H1299 cells using fluorescence microscopy. 
(B) Treatment scheme.   
Fig. 9A 
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3.3.3. The combination of 5-VdU and compound B impedes the progression of 
DNA replication forks and leads to accumulation of cells in mitosis 
 
To unravel the mechanism of cytotoxicity conveyed by the combination of 5-VdU and 
compound B, we have conducted a cell cycle analysis via flow cytometry (Fig. 10). 
H1299 cells were treated with 5-VdU for 24 h and subsequently with compound B for 
24 h (Fig. 10B). 48 h after the start of treatment, cells were halted in S-phase in the 
combination treatment condition and after 72 h cells accumulated at the G2/M cell 
cycle boundary (Fig. 10A). Furthermore, some cells progressed through mitosis after 
96 h, which is implied by a larger population of G1 phase cells, but at the same time 
an increase in sub-G1 cells can be observed. We therefore hypothesized that the 
combination is inducing cell death via DNA damage impacting mitosis, this is 
supported by the observation that cells start dying in the cell confluency assay only 72 
h after start of treatment (Fig. 8A & 8B). To visualize the possible effects on replication, 
a DNA fiber assay was conducted, cells were treated with 5-VdU for 24 h, 
subsequently with compound B for 24 h and then labelled for the DNA fiber assay (Fig. 
11D). Compound B decreases the replication fork speed by itself, but it is even further 
reduced by the combination treatment (Fig. 11A, 11B & 11C). We can therefore show 
that the combination of 5-VdU and compound B indeed slows down DNA replication, 
which explains the accumulation of cells in S-phase in the flow cytometry experiment 
(Fig. 10A). Furthermore, a Western Blot analysis of H1299 cells 24 h post compound 
B treatment (Fig. 11E & 11F) shows an immense accumulation of phospho-histone 3 
at Ser 10 (pH3)118, which indicates cells in M-phase, this observation also fits with the 
cell cycle profile at 72 h after start of treatment. 
 
As a sub-G1 cell population was observed after the mitotic arrest at 96 h post start of 
treatment, we wanted to observe the cell nuclear morphology 72 h post start of 
treatment (Fig. 12). Live cells were treated with Hoechst nuclear stain at the indicated 
time point (Fig. 12E) and then observed with fluorescence microscopy (Fig. 12A). 
While the treatment conditions of 5-VdU and compound B alone looked comparable 
to the DMSO control, strong morphological aberrations could be observed in the 
combination treatment condition. For one, nuclei in metaphase were far more 
abundant than in the controls (Fig. 12B & 12D), furthermore the nuclei were in average 
larger in the combination treatment condition (Fig. 12C). From these findings we 
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hypothesize, that the DNA damage inflicted by the combination of 5-VdU and 
compound B most likely impact cells in mitosis, which then leads to cell death. 
 
 
Figure 10: (A) Cell cycle analyses of H1299 cells show mostly unperturbed cell cycle 
profiles upon treatment with 0,5μM 5-VdU or 5μM compound B alone for the indicated 
periods of time. The combination of the two drugs leads to the accumulation of cells 
in S-phase at 24h, near the G2/M boundary at 72h and 96h, and additionally in a sub-













Figure 11: (A) H1299 cells were subjected to the DNA fiber assay after 24 h of 5-VdU 
and 24 h of compound B treatment.  (B) Distribution of replication fork speeds. The 
labelled tracks were classified to histograms, reflecting the number of forks with a 
speed between the indicated numbers (kb/min) and the next 0.1 digit. The percentage 
of tracks within each class is displayed by the columns. (C) Representative images of 
DNA fibers in the experiment. (D) Treatment scheme. (E) Western Blot analysis of 
H1299 cells 24 h post compound B treatment. (F) Treatment scheme of 4E. 
 








Figure 12: (A) Fluorescence microscopy of 10μM Hoechst 33342 stained H1299 cells 
treated for 24h with 5-VdU and 24h with compound B and further incubated without 
drugs for another 24h. (B) Mitoses per 100 cells, measured using cell counter in 
ImageJ. (C) Normalized nuclear surface area, measured using ROI manager in 
ImageJ. (D) Cells treated with 5-VdU and compound B, a disturbed metaphase cell is 
visible. (E) Treatment scheme.   
 
3.3.4. Nutlin-3a selectively protects cultured cells against the combination of 5-
VdU and compound B based on the p53 mutation status 
 
To implement the bio-orthogonal reaction of 5-VdU and compound B into a 
cyclotherapy approach, we have pretreated HCT116 p53 +/+ cells with Nutlin-3a for 
24 h prior to the combination treatment (Fig. 13A & 13D). All Nutlin-3a pretreated cells 
were temporarily impaired in cell proliferation, but the chemical did protect against the 
combination of 5-VdU and compound B (Fig. 13A). To test the dependency on p53 
protein functionality of this effect, we used the isogenic p53 -/- HCT116 cell line for the 
same experimental setup, and as a result, Nutlin-3a pretreatment failed to protect p53 
-/- cells against the combination of 5-VdU and compound B (Fig. 13B). We have further 
conducted Western Blot analyses to visualize the impact of Nutlin-3a mediated 
protection on DNA damage markers in these isogenic cell lines (Fig. 13C). As 
expected, the phosphorylation of Chk1 (pChk1) was reduced and the phosphorylation 
of yH2AX was strongly reduced in Nutlin-3a pretreated conditions in the p53 +/+ cell 
line. Furthermore, this signal reduction could not be observed for the HCT116 p53 -/- 
cell line, the signals for pChk1 and yH2AX were even intensified in the Nutlin-3a 
pretreated conditions. In conclusion, the protection via Nutlin-3a against the 











Figure 13: Pharmacological protection against the combination of 5-VdU / Compound 
B via Nutlin-3a in a p53 status dependent manner: (A) Pre- and co-treatment with 
Nutlin-3a protects HCT116 p53 +/+ cells against 5-VdU / Compound  B induced 
synthetic lethality, but fails to do so in (B) the isogenic HCT116 p53 -/- cell line. (C) 
Western Blot analysis shows that Nutlin-3a pre-treatment prevents phospho-Chk1 and 






Our data provide insight to a potent pretargeting strategy with the combination of 5-
VdU and compound B, which can be incorporated into a cyclotherapy approach, via 
Nutilin-3a pretreatment, to target p53 mutated cells specifically. We believe the 
combination of 5-VdU and compound B to be more powerful than Gemcitabine in this 
setup, as the latter induces a cell cycle arrest in targeted cells87,119. In contrast, 5-VdU 
incorporates throughout the genome, providing a much larger target surface, on which 
compound B could be applied with an otherwise cell cycle arrest inducing high dose 
concentration. Furthermore, the entire setup is modular, as 5-VdU could serve as a 
reaction partner for any tetrazine-coupled molecule.  
 
Bio-orthogonal synthetic lethality has been previously described with the combination 
of POM-AmdU and DiMOC114. Put into perspective, the combination of 5-VdU and 
compound B presents itself as the superior combination, as lower concentrations of 
either compound is needed to induce a stronger cytotoxic effect. Furthermore, 
compound B can be directly detected via fluorescence microscopy in living cells. This 
characteristic might be utilized for tumor localization in cancer surgery. Such an 
approach is already established in neurosurgery using the compound 5-Aminolevulinic 
Acid (5-ALA)120,121 and in clinical trials for intraoperative detection of 
Carcinoembryonic Antigen (CEA) using monoclonal fluorescent antibodies against 
CEA122. Cancer surgery conducted in this way might be beneficial due to better 
evaluation of safety distances and detection of micro-metastases.  
 
Our promising results legitimize the experimental evaluation in a mouse model. We 
are planning to use the KPC cells as a xenograft. However, a recent study has 
reported that Nutlin drugs might not have the same potency in mice as in humans123. 
As an alternative, the retinoblastoma protein (pRb) mutation might serve as a potential 
target, as it can be indirectly targeted through CDK4/6 inhibitors124. Such inhibitors are 
already used in the clinical routine for treatment of advanced and metastatic breast 
cancers125, in which they halt tumor progression by cell cycle arrest induction. Small 
cell lung cancer is a suitable tumor entity to study the effects of the bio-orthogonal 
combination regimen, as these cancers most commonly lose both pRb and p53126.  
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The concept of pretargeting has already been extensively investigated in 
radiotherapy105. Due to the modular nature of the pretargeting approach, a bio-
orthogonal reaction between a nucleoside analogue and a radionuclide would also be 
possible. The prerequisite for the functionality would be the nuclear localization of the 
radionuclide, which should be short-range acting. The most suitable high energy 
particles for such a purpose are Auger electrons which are formed after electron 
capture from a higher energy level. Most of the excess energy is emitted as X-ray 
energy, but some is released as kinetic energy given to another electron, then called 
Auger electron, which is emitted127. The most common Auger-electron-emitters are 
iodine isotopes, which are frequently used in nuclear medicine clinical routine. The 
nuclear targeting of such a drug has been of great interest in the targeted radionuclide 
therapy (TRT) community, as the induced DNA damage would be most intense with a 
nuclear localized radionuclide128. Furthermore, it would be similarly beneficial to 
couple a radiosensitizer to DNA of cancer cells129,130, which might improve the 
therapeutic index for radiation therapy. Taken together, the incorporation of a 
radionuclide or a radiosensitizer into the cyclotherapy and pretargeting regimen might 
be effective for treating tumor suppressor mutated cells in cancer patients.  
 
The advances of nanotechnology prompt the idea to bio-orthogonally attach 
nanomaterials to DNA-incorporated nucleosides. They can, as an example, be utilized 
for thermal ablation131 or any other designable purpose132. The attachment of an 
enzymatic compound on the DNA, which activates a DNA damaging compound, would 
be of great interest to target tumor suppressor mutated cancer cells specifically133.  
 
In summary, the bio-orthogonal combination of 5-VdU and compound B presents itself 
as a powerful combination to treat p53 mutated cancer cells in a pretargeting, Nutlin-
3a mediated cyclotherapy approach. Put in a bigger picture, the pretargeting with 
nucleosides, which at the same time act as a bio-orthogonal reaction partners, may 
serve as a modular platform for chemotherapy, cancer surgery, radiotherapy and 
beyond. It is the current mission to find functional compounds with the desired effects 







DNA stands at the center of cancer disease and therapy. In our work, we have shown 
the context related modulation of established DNA damaging chemotherapeutic drugs 
with novel compounds, i.e. Gemcitabine or cisplatin in combination with MK2 
inhibitors. The different outcomes of the drugs are based on the different effects MK2 
inhibition has on the DNA damage response, DNA repair and cell cycle regulation. 
The modulation of DNA damage pathways therefore represents an opportunity for 
finding novel chemotherapeutic targets for clinical cancer treatment, although these 
findings will be specifically context related. The correct identification of the specific 
context and application of the suitable treatment will be solved by the onset and 
establishment of personalized medicine patient big data. In another part of this 
dissertation, we have successfully applied the concept of cyclotherapy with a high 
potency in vitro, prompting application in an experimental mouse model. This will be a 
difficult task to accomplish, as the in vivo application of cyclotherapy will demand a 
careful titration and timing of the treatments given. We will discuss current synthetic 
lethality drug regimens and the up to date knowledge on tumor suppressor 
pharmacological activators in the upcoming sections. 
 
4.1. Drug combinations and synthetic lethality 
 
The aim of novel combinations between established chemotherapeutics and newly 
discovered compounds is the exacerbation of cytotoxicity. We were able to show in 
the same biological system, that MK2 pharmacological inhibition protects cells against 
the S-phase drug Gemcitabine, but sensitizes against cisplatin, which mainly impacts 
mitosis134. Possible applications of MK2 inhibitors in the clinics are therefore strictly 
context related. It has been recently reported that the p38-MK2 axis plays an important 
role in RNA metabolism upon the DNA damage response to UV-light irradiation135. In 
more detail, p38 and MK2 mediate the removal of Negative Elongation Factor E 
(NELFE) from chromatin through 14-3-3 protein binding, by phosphorylation at 
Ser115, which ensures the elongation of transcription. Ongoing transcription can be 
beneficial or detrimental for the DDR136. Our group has previously reported the 
protective effects of MK2 loss of function against UV-light irradiation in vivo, MK2/MK3 
deficient mice showed less induction of apoptosis in skin keratinocytes upon UV-light 
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irradiation as compared to control animals62, this might hint at a cellular protective role 
of MK2 inhibition in the context of UV-light irradiation. Our results and the current 
literature exemplify the specific context relatedness in the application of novel targeted 
compounds for personalized medicine.  
 
4.1.1. PARP inhibition 
 
The onset of personalized medicine, i.e. the large scale and high-throughput 
sequencing of patient DNA, RNA and protein sample data, will help to put novel 
chemotherapeutic drugs into the correct biological context137. The concept of synthetic 
lethality, meaning the identification of vulnerable targets upon a specific cancer cell 
mutation138, is a very promising direction for DDR and DNA repair pathway related 
drug development. The beauty of the system is that only cancerous cells would be 
susceptible to the treatment, whereas non-transformed cells would not be affected to 
the same degree. One success story of synthetic lethality is the development of Poly-
ADP-ribose polymerase (PARP) inhibitors, which are now routinely applied to patients 
with breast and ovarian cancers139. PARP mediated attachment of ADP-ribose is 
crucial for the recognition and repair of DNA SSBs, which will, if unrepaired, progress 
into highly cytotoxic DNA DSBs33. As a consequence, if DSB repair is impaired in a 
cell, a window for synthetic lethality therapeutic options opens. This is the case for 
breast and ovarian cancers that carry Breast Cancer gene (BRCA) 1/2 mutations, as 
BRCA proteins play a central role in DSB repair140,141. The generation of DSB through 
PARP inhibition exacerbates DNA damage in BRCA mutant cells that fail to undergo 
DNA DSB repair. Furthermore, other mutations in the DSB repair pathway mimic 
BRCA mutations and would similarly respond to PARP inhibition, this phenomenon 
has been termed “BRCAness” and significantly broadens the clinical indications for 
PARP inhibitors142. Due to the firm establishment of PARP inhibitors in clinical 
oncology, numerous mechanisms of drug resistance have also been elucidated, one 
of them being the dysregulation of DNA repair pathway choice. DNA DSBs are 
repaired by a careful equilibrium between homologous recombination (HR) and non-
homologous end joining (NHEJ). The loss of BRCA proteins tilt the balance towards 
NHEJ, which is error-prone and can lead to catastrophic chromosomal 
rearrangements. While BRCA proteins control HR, 53BP1 mediates NHEJ repair of 
DSB, an additional 53BP1 loss in a BRCA mutant background therefore inactivates 
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NHEJ and restores HR, rendering the cell less susceptible towards PARP inhibition143. 
The successful clinical application of PARP inhibitors show the importance of 
understanding the DDR and DNA repair pathways in molecular detail. Further 
research could reveal even more potent drug combinations and possibilities to 
overcome mechanisms of drug resistance. 
 
4.1.2. DNA damage pathways and checkpoint inhibitors 
 
A recent breakthrough in clinical cancer therapy was the successful application of 
checkpoint inhibitors, which are therapeutic antibodies against the immunological 
epitopes Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA4), Programmed cell 
Death protein 1 (PD-1) and PD-Ligand 1 (PD-L1)144. These factors are able to dampen 
the immune response upon an immunologic stimulus. CTLA4 and PD-1 are 
transmembrane receptors expressed on activated T-cell membranes, whereas PD-L1 
is the corresponding ligand for PD-1 expressed on a target cell surface, leading to its 
veiling from the immune system. CTLA4 mainly acts on T-cell activation in lymphatic 
tissue, while PD-1/PD-L1 mediates the inhibition of effector T-cells and NK cells in 
peripheral tissues145. As a subgroup of cancers utilize these checkpoint factors to 
protect themselves from the patient immune system, checkpoint inhibitor therapy can 
overcome this protection and restore immune function, rendering these tumors 
vulnerable again. Most interestingly, a recent intracellular signalosome has revealed 
ATM and ATR as interaction partners of PD-L1, most likely in the nucleus146,147, 
suggesting that ATM/ATR co-inhibition could potentiate checkpoint inhibitor blockades 
and help overcome mechanisms of resistance148,149,150. Furthermore, multiple DNA 
repair pathways have been implicated in PD-L1 regulation, such as DNA mismatch 
repair (MMR)151,152, DNA DSB repair153 and DNA base excision repair (BER)154. For 
instance, DSB signaling through ATR/Chk1 activate the STAT1/3-IRF1 pathway, with 
IRF1 directly upregulating PD-L1 mRNA transcription153,155. Currently, the study of 
checkpoint protein interactions with DDR and DNA repair, as well as the evaluation of 
possible biomarkers from these pathways, are promising approaches to complement 





4.2. Tumor suppressor activating drugs revisited 
 
The discovery of p53 activating drugs was at first met with great excitement, as the 
successful targeting of such an important protein would revolutionize cancer 
medicine156. p53 proficient cancer cells are often dysregulated in the p53 pathway, 
pharmacological activation would therefore strongly reactivate p53 functions 
independently from other factors. Such treatment would mediate arrest of the cell cycle 
and apoptosis, severely impacting cancer cell survival. And indeed, preclinical testing 
revealed Nutlin-3a induced cytotoxicity in p53 proficient cell lines and in mouse 
xenografts85, with MDM2 overexpressing cancer cells being the most vulnerable to the 
treatment. The p53-activating drug RG7112 was then cleared for clinical trials, using 
a 20 patient cohort suffering from liposarcoma, which commonly exhibits an MDM2 
amplification110. The outcome was disappointing. Not only was the response limited to 
1 partial response and 14 stable disease patients, but the array of side effects ranged 
from severe to life threatening, with 6 patients suffering from neutropenia and 3 
patients from thrombocytopenia. Taken together, the results were not as expected and 
would limit the clinical applications of p53 stabilizing drugs. The interest in RG7112 
was lost, however, a more potent Nutlin-3a analogue with superior potency and 
selectivity, RG7388 or Idasanutlin157, currently has 15 entries on the ClinicalTrials.gov 
website, the clinical trials were designed for targeting various hematological 
malignancies and solid tumors. Next generation Nutlins might therefore really find their 
way into the clinical routine.  
 
The application of p53 activators for the cyclotherapy approach remains of great 
interest. The use of an analogue with great potency and selectivity, such as 
Idasanutlin, would be favorable for this purpose. However, the final proof of principle 
in vivo has not yet been provided, as such animal experiments are very sophisticated, 
the careful titration and timing in a whole organism is not easily done. Another 
important factor is the chemotherapeutic drug, which should be protected against. 
Only a very suitable and effective candidate would justify such an intricate 
experimental mouse model. We hope to have provided evidence for such a promising 
candidate in the combination of 5-VdU and Compound B. Aggravating the matter, a 
recent report has revealed a difference in effectivity of MDM2 antagonists between 
human and murine cell lines, the difference being larger if the Nutlin is more specific 
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and potent in human cell lines, i.e. the difference in Idasanutlin effectivity would be 
larger than the Nutlin-3a effectivity difference123. Paving the way to cyclotherapy 
clinical trials through an experimental mouse model using Idasanutlin might therefore 
be even more complicated as anticipated. As an alternative, upon a pRB mutation, the 
Cdk4/6 inhibitor Palbociclib (Ibrance®) could be utilized as a tumor suppressor 
activating drug for the cyclotherapy regimen124. Palbociclib is already routinely given 
to patients with advanced and metastatic breast cancers to induce tumor cell cycle 
arrest125, it can be taken orally and is in average well tolerated, with one daily dose 
over a course of 21 days158. The possible application for Palbociclib in a cyclotherapy 
experimental setup would be feasible in a small cell lung cancer model, as these 
cancers are very aggressive and commonly lose both pRb and p53126. In summary, 
the final proof of principle for cyclotherapy is yet to be provided in vivo and the 
discovery of more pharmacological activators of tumor suppressor proteins could be 















4.3 Specific targeting of cancer cells with tumor suppressor mutations 
 
4.3.1. Improvement of the current cyclotherapy model 
 
The combination of the cyclotherapy approach with the pretargeting model is superior 
to cyclotherapy without pretargeting due to a number of reasons: Without pretargeting, 
the use of a DNA replication toxin, such as Gemcitabine, would arrest the cell cycle in 
tumor suppressor mutated cells after initial exposure to the substance119. Furthermore, 
a higher dosage of Gemcitabine would arrest the cell cycle faster. As a consequence, 
both of these effects limit the effective drug concentration in the cancer cell nucleus. 
Pretargeting solves both these problems. For one, non-genotoxic incorporation of a 
nucleoside analogue does not arrest the cell cycle and labels most of the genome. In 
addition, the nucleoside analogue can be given at a low concentration, whereas the 
partner drug can be upscaled to a high concentration, as p53 proficient cells would 
have not incorporated the nucleoside analogue and arrested their cell cycle, rendering 
them insusceptible to the second drug. This ensures the entire p53 mutant cancer cell 
genome to be targeted by a high dose of the cytotoxic pretargeting component. 
Furthermore, a potentiation of the effects could be accomplished by applying 
additional substances or extracorporal factors. As an example, certain nanoparticles 
attached to DNA could be activated by magnetism or ultrasound to produce heat for 
tumor thermal ablation131. Also, the attachment of nanozymes to DNA could turnover 
a non-toxic substrate into a cytotoxic product159. The success of this type of strategies 













Figure 15: Schematic representation of the labeling extent of treated cell nuclei: WT = 
tumor suppressor wild type, mut = tumor suppressor mutated, A = tumor suppressor 
activating drug, NA = nucleoside analogon compatible for Click Chemistry reaction, 
Gem = Gemcitabine, Y = cytotoxic drug component, Z = additional cues, such as 
magnetism or ultrasound for thermal ablation. (A) Without cyclotherapy, WT and mut 
cells are both labeled with the NA and suffer severe cytotoxic effects upon the addition 
of Y. (B) Upon the activation of the tumor suppressor, only mut cells incorporate the 
NA and are subsequently susceptible for Y and subsequently Z, while WT cells remain 
unharmed due to an arrested cell cycle. (C) In comparison, cyclotherapy with 
Gemcitabine offers a smaller DNA target surface, as the genome will only be partially 
impacted due to a genotoxic drug induced cell cycle arrest. 
 
 
4.3.2. A versatile tool for cancer therapy 
 
Our findings suggest the possibility of specifically targeting the DNA of tumor 
suppressor mutated cancer cells in a patient. Multiple benefits arise from this model. 
For one, the induction of cytotoxicity, only in cancer cells, strongly reduces 
chemotherapeutic side effects93. Furthermore, p53 mutations arise late in 
carcinogenesis and are correlated with aggressive behavior of the cancer160. 
Targeting these cells should provide a large therapeutic benefit for the patient. Most 
importantly, with the DNA being of pivotal importance for a cancer cell, the direct 
targeting of DNA provides multiple advantages to impede tumor growth and survival29. 
Classical DNA damaging approaches, such as chemotherapy and radiotherapy, could 
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be augmented in our model. The incorporated nucleoside analogue provides a 
multimodal platform for the reaction with various compounds of interest. Novel and 
established chemotherapeutics could be crosslinked with DNA and therefore enriched 
in the tumor suppressor mutated cancer cell nucleus. The DNA could be intra- and 
interstrand-crosslinked through a modulator and a catalyst (Fig. 9B and 11B). For 
radiotherapy, the crosslinking of established radiosensitizers161 and oxygen enriching 
substances162 would potently and specifically enhance the effects of therapeutic 
irradiation. The use of the pretargeting cyclotherapy scheme in nuclear medicine 
would give rise to different perspectives. For one, the incorporation of radioactive 
emitters127 could already damage cancer cells specifically, but the provided activation 
energy also sets the stage for switchable compounds163. A recent report shows such 
an activation of a photo-switchable chemotherapeutic by a radioemitter. The drug was 
specifically delivered into cancer cells by targeted nanomicelles, with a 
radiopharmaceutical circulating in the bloodstream in vivo133, suggesting that a 
switchable compound on the incorporated nucleoside analogue could be activated in 
a similar manner. Furthermore, incorporated radioemitters could be used for 
imaging164, whereas fluorescent substances could find their application in intra-
surgical in situ tumor detection, similar to 5-Aminolevulinic Acid (5-ALA) in 
neurosurgery120.  The successful proof of principle of the cyclotherapy-pretargeting 
combined approach would give rise to a versatile theranostics tool for specifically 





Figure 16: Reactions on nucleoside analogues: X = Click chemistry reaction partner 
1, Y = Click chemistry reaction partner 2, Cat = catalyst. (A) Bioconjugation at 
nucleoside analogue. (B) Dimerisation of nucleoside analogues. 
 
  
Figure 17: Schematic of the possibility to simultaneously apply up to 4 different 










Figure 18: (A) Schematic reaction from Figure 16A. (B) Schematic reaction from 
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6. Supplemental information 
6.1. Supplemental figures for manuscript I 
 
Supplemental Figure S1: 
Quantification of phospho-HSP27 
normalized to Actin corresponding 
to figure 2A. Western blot band 
intensities of different time points were 
quantified using the ImageJ software. 
Error bars represent the standard error 




Supplemental Figure S2: Comparison of sorbitol with gemcitabine and 
cisplatin, regarding MK2 localization and activation. A. Quantification of nuclear 
or cytoplasmic localization of MK2-myc overexpressing cells corresponding to figure 































































Supplemental Figure S3: Distribution of track lengths in all fiber assays, 
corresponding to figures 4 and 5.  Three replica are shown for each condition, with 
the mean and SEM of the track lengths (left), along with the distribution of track lengths 
(right).  A. Experiments conducted in Panc1 cells, treatment with gemcitabine and MK2 
inhibitor as in Fig. 4, B-E.  B. Experiments conducted in Panc1 cells, treatment with 
5 μM cisplatin and MK2 inhibitor for 24 h. Note that this concentration of cisplatin, albeit 
far greater than the amount required for compromising cell viability (0.5μM, cf. Fig. 1 
B), is still insufficient for detectable reduction in replication fork progression.  C. 
Experiments conducted in Panc1 cells, treatment with 10μM cisplatin and MK2 
inhibitor III, as in Fig. 5.  D. As in A, but experiment conducted in MIA PaCa-2 cells 
and adding PF3644022 to the drug panel.  E. As in C, but experiment conducted in 
MIA PaCa-2 cells with 50μM instead of 10μM cisplatin and adding PF3644022 to the 























6.2 Supplemental figures for manuscript II 
 




Supplemental Figure SII-1: Distribution of track lengths fiber assays, 
corresponding to figure 4. Three replica are shown for each condition, with the 
mean and SEM of the track lengths (left), along with the distribution of track lengths 
(right). Experiments conducted in H1299 cells, treatment with 5-VdU and compound 





°C                     Degree Celsius 
μl                    Microliter 
μM       Micromolar 
ATM                   Ataxia telangiectasia mutated 
ATR                     ATM and Rad3-related 
ATRIP                    ATR interacting protein 
BRCA    Breast cancer gene 
BSA                    Bovine serum albumin 
CAK                    CDK-activating kinase 
CDK                    Cyclin-dependent kinase 
Chk1                    Checkpoint kinase 1 
Chk2                     Checkpoint kinase 2 
CTLA4   Cytotoxic T-Lymphocyte-Associated protein 4 
CuAAC   Copper catalyzed Azide-Alkyne Click reaction 
dFCTP   2',2'-difluorodeoxycytidine triphosphate 
DDR    DNA damage response 
DMSO                 Dimethylsulphoxide 
DNA                  Deoxyribonucleic acid 
dsDNA   Double stranded DNA 
DSB     Double stranded DNA break 
H2AX                    Histone variant 2AX 
H2O                    Water 
HR    homologous recombination 
kDa       Kilodalton 
M                       Molar 
MAPK    Mitogen activated protein kinase 
MDM2            Mouse double minute 2 
mg      milligram 
min      minute 
ml                      milliliter 
mM    milimolar 
MRN                  MRE/Rad50/NBS1 
 84 
mRNA                   messenger RNA 
NHEJ    non-homologous end joining 
NER    nucleotide excision repair 
PARP    Poly-ADP-Ribose-Polymerase 
PBS                    phosphate buffered saline 
PCNA    proliferating cell nuclear antigen 
PD-1    Programmed cell Death protein 1 
PD-L1    PD-Ligand 1 
PI    Propidium Iodide 
pRb    retinoblastoma protein 
ROS    Reactive oxygen species 
RNA                     ribonucleic acid 
RPA                     replication protein A 
SDS                  sodium dodecyl sulfate 
SDS-PAGE                SDS polyacrylamide gel electrophoresis 
SPAAC   Strain-promoted Azide-Alkyne Click reaction 
SSB    Single stranded DNA break 
ssDNA                    single stranded DNA 
TBST                   Tris buffered saline + Tween20 
Tris       Trisamine 
UV                     Ultraviolet 
V                       Volt 
VdU    5-Vinyl-2'-deoxyuridine 
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